{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:54:28Z","timestamp":1783464868937,"version":"3.55.0"},"reference-count":17,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Second-generation Bruton's tyrosine kinase (BTK) inhibitors, acalabrutinib and zanubrutinib, are preferred agents for the treatment of relapsed and\/or refractory mantle cell lymphoma (MCL) over first-generation BTK inhibitor, ibrutinib. The comparative safety and efficacy of these two agents have not been studied. Currently, the decision between using one second-generation BTK inhibitor over the other is largely dependent on provider preference, cost, organ dysfunction, presence of drug\u2013drug interactions, adherence considerations, and theorized differences in safety outcomes due to the lack of head-to-head trials in MCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, observational study seeks to provide real-world data on the safety and efficacy of second-generation BTK inhibitors in the setting of relapsed and\/or refractory MCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-eight patients treated with a second-generation BTK inhibitor were evaluated. Ten percent of patients experienced a select adverse drug event (ADE) in the acalabrutinib group that included hypertension and major hemorrhage with no patients experiencing a select ADE in the zanubrutinib group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results support historical data that acalabrutinib and zanubrutinib have a more favorable safety profile compared to ibrutinib in MCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241232331","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T01:50:00Z","timestamp":1707961800000},"page":"230-235","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6589-0908","authenticated-orcid":false,"given":"Jessie","family":"Lu","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Do","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6553-0155","authenticated-orcid":false,"given":"Brian","family":"Primeaux","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4345"},{"key":"e_1_3_4_3_2","unstructured":"Imbruvica [package insert]. Horsham PA: Janssen Biotech Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/205552s035 215063s011lbl.pdf. Accessed Aug 22 2022."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00638-0"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125800"},{"key":"e_1_3_4_6_2","unstructured":"Update on IMBRUVICA\u00ae (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications | AbbVie News Center. news.abbvie.com. Accessed June 09 2023. https:\/\/news.abbvie.com\/news\/press-releases\/update-on-imbruvica-ibrutinib-us-accelerated-approvals-for-mantle-cell-lymphoma-and-marginal-zone-lymphoma-indications.htm"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201817"},{"key":"e_1_3_4_8_2","unstructured":"National Comprehensive Cancer Network. B-Cell Lymphomas (Version 2.2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf Accessed Feb 13 2023."},{"key":"e_1_3_4_9_2","first-page":"39","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","author":"Byrd JC","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 2021; 39: 441\u20133452.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630942"},{"key":"e_1_3_4_12_2","unstructured":"Calquence [package insert]. San Mateo CA: BeiGene USA Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/216387Orig2s000Correctedlbl.pdf. Accessed Aug 22 2022."},{"key":"e_1_3_4_13_2","unstructured":"Brukinsa [package insert]. Horsham PA: Janssen Biotech Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/213217s005lbl.pdf. Accessed Aug 22 2022."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01252-y"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005621"},{"key":"e_1_3_4_16_2","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 November 2017 National Institutes of Health National Cancer Institute. (Accessed August 22 2022)."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1008"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241232331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241232331","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241232331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:32Z","timestamp":1777688972000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241232331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/10781552241232331"],"URL":"https:\/\/doi.org\/10.1177\/10781552241232331","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]}}}